Introduction
============

Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of poorly differentiated non-small-cell lung cancer (NSCLC) and is defined as carcinoma with pleomorphic, sarcomatoid, or sarcomatous elements. It can be divided into five histological types as follows: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma.[@b1-ott-12-3321] As a rare form of lung malignancy, PSC has a significantly worse prognosis compared with other forms of NSCLC.[@b2-ott-12-3321] Chemotherapy and oral administration of small molecule tyrosine kinase inhibitors (TKIs) are commonly used in the treatment of NSCLC. Before choosing chemotherapy or molecular targeted therapy, genes such as EGFR, *ALK*, ROS1, and *KRAS* should be analyzed. Although the incidence rate of *ALK* rearrangement in NSCLC is \<5% and that of *KRAS* mutation ranges from 24% to 27.6%,[@b3-ott-12-3321]--[@b5-ott-12-3321] *ALK* rearrangements are mutually exclusive with mutations in EGFR or *KRAS*.[@b3-ott-12-3321],[@b4-ott-12-3321],[@b6-ott-12-3321] Only a few NSCLC patients have both *KRAS* mutation and *ALK* rearrangement, and concomitant *KRAS* mutation and *ALK* rearrangement in PSC has not been reported so far.

NSCLC accompanied by *ALK* rearrangements is highly sensitive to *ALK* TKIs, such as crizotinib and ceritinib.[@b7-ott-12-3321]--[@b9-ott-12-3321] However, *KRAS* mutations may decrease the efficacy of chemotherapy and oral molecular targeted therapy to NSCLC.[@b10-ott-12-3321]--[@b13-ott-12-3321] It has been reported that PSC is highly resistant to conventional first-line chemotherapy.[@b14-ott-12-3321]--[@b16-ott-12-3321] However, the response of *KRAS* mutation and *ALK* fusion-positive PSC to chemotherapy and molecular targeted therapy remains largely unexplored. In the present work, we report a case of PSC with coexistent *KRAS* exon 2 mutation and EML4-*ALK* fusion, who failed to respond to chemotherapy and crizotinib.

Case presentation
=================

A 61-year-old male patient was hospitalized on February 5, 2018, because of cough and dyspnea. The patient had been ill for the past 15 days, exhibiting cough, dyspnea, and right chest pain. Computed tomography (CT) showed spot- and piece-shaped shadows. The patient was treated with cefoperazone--sulbactam in the early stage due to a preliminary diagnosis of pneumonia. However, anti-pneumonia therapy failed, and his condition worsened. He presented symptoms of extreme breathing difficulty and was hospitalized. Physical examination revealed dull sound by percussion and decreased breath sounds in the right lateral lung areas by auscultation. The second CT scan revealed a large amount of pleural effusion in the right lateral pleural cavity. He was diagnosed with bloody pleural effusion through pleural space puncture. Biopsy pathology and immunohistochemistry examination can be seen in [Figure 1](#f1-ott-12-3321){ref-type="fig"}. Thoracoscopy revealed multiple nodular lesions in the right pleural cavity ([Figure 1A](#f1-ott-12-3321){ref-type="fig"}). Lesion tissues were collected for biopsy. PSC was confirmed through biopsy and histopathology ([Figure 1B](#f1-ott-12-3321){ref-type="fig"}). IHC showed tumor cells positive for CK7 (clone MX053; [Figure 1C](#f1-ott-12-3321){ref-type="fig"}) while being negative for TTF-1 (clone MX011), Napsin A (clone MX015), CK5/6 (clone D5/16B4), Calretinin (clone SP13), WT1 (clone WT49), and MC (clone HBME-1). After thoracoscopy, CT revealed spot- and piece-shaped shadows and multiple solid lesions in the right lung as well as nodular pleural thickening ([Figure 2A](#f2-ott-12-3321){ref-type="fig"}). Moreover, the enlargement of mediastinal lymph nodes was also observed. Single-photon emission CT (SPECT) scan revealed multiple bone metastases ([Figure 2B](#f2-ott-12-3321){ref-type="fig"}). To make a treatment choice, nine genetic tests including EGFR, *KRAS*, ROS1, BRAF, NRAS, PIK3CA, HER-2, RET, and *ALK* were performed by amplification refractory mutation system (ARMS)-PCR. The ARMS-PCR revealed *KRAS* exon 2 mutation and EML4-*ALK* fusion, while the EGFR, ROS1, BRAF, NRAS, PIK3CA, HER-2, and RET genes were wild type. We further verified the *KRAS* exon 2 mutation by performing Sanger's sequencing to analyze the *KRAS* gene sequence (an arrow shows code 12 GGT to GAT; [Figure 3A](#f3-ott-12-3321){ref-type="fig"}). *ALK* rearrangement was also further confirmed by examining *ALK* expression (clone D5F3; Hoffman-La Roche Ltd., Basel, Switzerland) using IHC ([Figure 1D](#f1-ott-12-3321){ref-type="fig"}) and FISH assay ([Figure 3B](#f3-ott-12-3321){ref-type="fig"}). The patient was finally diagnosed as PSC T4N3M1C stage IVB *KRAS*(+) *ALK*(+). From February 14, 2018, to March 5, 2018, the patient received one cycle of first-line combination chemotherapy of cisplatin and paclitaxel liposomes. However, the platinum-based combination chemotherapy did not work within 3 weeks. The patient's pleural effusion was still growing rapidly. He experienced breathing difficulty and exhibited a loss of appetite and fatigue. A repeat CT showed increased pleural effusion with further thickening of the pleura and presence of multiple nodules ([Figure 2C](#f2-ott-12-3321){ref-type="fig"}). Based on the CT results, the patient was orally administered with crizotinib instead of chemotherapy. Unfortunately, he still exhibited rapid disease progression and died on April 2018, 2 weeks after the initiation of crizotinib treatment.

Discussion
==========

PSC is a rare, poorly differentiated, and highly aggressive type of NSCLC.[@b2-ott-12-3321] Radiotherapy, chemotherapy, and TKIs are commonly used in the treatment of advanced NSCLC. In patients with *ALK* fusion-positive NSCLC, small molecule TKIs are more efficient compared with the platinum-based combination chemotherapy. For example, NSCLC with *ALK* rearrangements is susceptible to the *ALK* TKI, crizotinib, and the overall response rate is as high as 70%--80%.[@b9-ott-12-3321],[@b17-ott-12-3321] Moreover, only few NSCLC patients have multiple oncogenic mutations, and coexistence of *ALK* rearrangement and *KRAS* mutation accounts for only \~13% of the multi-gene mutations.[@b18-ott-12-3321] Therefore, crizotinib is the preferred therapeutic scheme for patients with *ALK* fusion-positive NSCLC.

In the present case, the patient, diagnosed with PSC positive for *KRAS* exon 2 mutation and EML4-*ALK* fusion, could not receive surgery or radiation as he was in late-stage disease. PSC is a rare type of lung cancer, and PSC with coexistent *KRAS* mutation and *ALK* fusion has never been reported before. There is no experience of success or guideline for treatment of such disorders in clinical practice. Referring to the commonly used treatment for NSCLC, the patient should be treated with crizotinib because of positive EML4-*ALK* fusion.[@b19-ott-12-3321] However, NSCLC may fail to respond to molecular targeted therapy because of adverse TP53 and *KRAS* mutations.[@b13-ott-12-3321] Moreover, in this patient, PSC progressed rapidly. If the patient failed to respond to oral administration of TKI crizotinib, he might never have another chance of chemotherapy. Therefore, after fully considering the benefits and potential risks, the patient preferred combination chemotherapy of cisplatin and paclitaxel. Unfortunately, the platinum-based combination chemotherapy failed, and the patient's condition deteriorated rapidly. Therefore, the patient was orally administered with crizotinib instead of chemotherapy. However, he failed to respond to the oral crizotinib treatment and died in April 2018.

As a very rare disease, there is still a lack of effective treatment for PSC. Surgical treatment should be considered first in the early stages. Advanced PSC always has a very poor prognosis and responds poorly to conventional platinum-based chemotherapy.[@b14-ott-12-3321],[@b20-ott-12-3321] It has been reported that *ALK* inhibitors may be an effective treatment for *ALK* rearrangement in PSC.[@b19-ott-12-3321] However, *KRAS* mutations can result in a detrimental impact on prognosis and responsiveness to platinum-based chemotherapy in NSCLC[@b18-ott-12-3321],[@b21-ott-12-3321] as well as in PSC.[@b14-ott-12-3321]--[@b16-ott-12-3321] In the present report, the patient with coexistent *KRAS* mutation and *ALK* rearrangement failed to respond to platinum-based chemotherapy, and his condition deteriorated rapidly even when he was administered the *ALK* inhibitor, crizotinib. The results of treatment, in this case, were consistent with the literature that *KRAS* mutations can result in primary resistance to crizotinib.[@b10-ott-12-3321]--[@b13-ott-12-3321] In recent years, high expression of PD-L has been reported in PSC,[@b22-ott-12-3321],[@b23-ott-12-3321] which can offer the therapeutic possibility of immunotherapy.[@b23-ott-12-3321]--[@b25-ott-12-3321] In addition to tumor PD-L1 expression being linked to *KRAS* mutations, higher response rates to anti-PD-L1 antibody treatment are also reported in the *KRAS*-mutated NSCLC.[@b25-ott-12-3321] Therefore, it is necessary to investigate the mechanisms underlying the PD1/PD-L1 immunological therapy in future studies.

Conclusion
==========

PSC is a rare, highly malignant NSCLC with poor prognosis, and there is no available effective treatment in clinical practice. Here, we report a case of PSC positive for *KRAS* exon 2 mutation and EML4-*ALK* fusion, who failed to respond to platinum-based chemotherapy. The patient's condition deteriorated rapidly even with *ALK* inhibitor, crizotinib treatment. Our results suggest that a PSC patient with coexistent *KRAS* mutation and *ALK* rearrangement would not benefit from chemotherapy and TKI treatment.
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![Biopsy pathology and IHC examination. (**A**) Thoracoscopic photography. Multiple nodular lesions were found in right pleural cavity under thoracoscopy. (**B**) Histopathological examination (H&E). The pleural tissue showed neoplasia, large nuclei, deep staining, and strong heterogeneity, which was similar to sarcoma. (**C**) IHC, DAB staining. It showed positive CK67 staining in tumor tissue. (**D**) IHC, DAB staining. It showed strong positive EML4-*ALK* staining in tumor tissue.\
**Abbreviation:** IHC, immunohistochemistry.](ott-12-3321Fig1){#f1-ott-12-3321}

![Images of CT and SPECT. (**A**) CT image. After thoracoscopy, most pleural effusion was drained. CT revealed spot- and piece-shaped shadows, showing multiple solid lesions in the right lung. (**B**) SPECT image. General bone scan showed multiple metabolic abnormalities and concentration points. (**C**) CT image. Pleural effusion increased further, and the pleura became much thickened with multiple nodules.\
**Abbreviations:** CT, computed tomography; SPECT, single-photon emission CT.](ott-12-3321Fig2){#f2-ott-12-3321}

![(**A**) Sanger's sequencing further confirms *KRAS* exon 2 mutation (the arrow shows code 12 GGT to GAT). (**B**) *ALK* rearrangement revealed by the split of red and green probes in FISH assay with 75% of rearranged cells.](ott-12-3321Fig3){#f3-ott-12-3321}
